Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.87

-2.3%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: robert miller who wrote (9449)	11/10/2003 2:09:56 PM
From: Ian@SI	of 52153

medscape.com Some of the issues related to open access to peer-reviewed publications... Opening paragraph follows... Pros and Cons of Open-Access Publishing Debated Emma Hitt, PhD Nov. 7, 2003 — Open-access publishing, or free access to peer-reviewed research articles, is the subject of two contrasting reports in this week's issue of The Lancet. The issue has come to the forefront due to the Public Access to Science Act, recently introduced into the U.S. House of Representatives by Democratis Rep. Martin O. Sabo from Minnesota. The act proposes that papers describing scientific research substantially funded by the U.S. government would be excluded from copyright protection, as a means to guarantee free access to this information. ...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next